SAN Sanofi

Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee

Press Release: Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee

Audrey Duval Derveloy appointed Global Head of Corporate Affairs, member of Sanofi’s Executive Committee

Paris, June 21, 2024. Audrey Duval Derveloy, a seasoned healthcare industry leader and Sanofi France’s President, has been named Executive Vice President, Global Head of Corporate Affairs. Audrey will become a member of Sanofi’s Executive Committee, reporting into CEO Paul Hudson, and will be based in Paris. Her appointment is effective July 1, 2024.

In her new role, Audrey will be responsible for Sanofi’s stakeholder engagement globally, and oversee the company’s corporate social responsibility strategy, not-for-profit Global Health Unit and Sanofi’s philanthropic arm, Foundation S. Audrey retains her role as President, Sanofi France, and will continue supporting and coordinating Sanofi’s representation to its various external stakeholders in this country.

Paul Hudson

Chief Executive Officer, Sanofi

“ I am very pleased to have Audrey join our Executive Committee. Over the last two years, her leadership has been instrumental in advancing our company’s modernization in France. She has supported our strategic priorities and helped showcase Sanofi as a leading healthcare company in our home market. This recent experience, coupled with her business acumen and ability to inspire and motivate teams, paves the way for her to drive our global external engagement strategy and play a decisive part in our ambitions to become a science-driven company transforming the practice of medicine for patients across the world.”

Audrey joined Sanofi from Novartis to serve as President, Sanofi France, in September 2022. A physician by training, she started her career in public hospitals in Paris. She then worked as a Researcher at the Pasteur Research Center of Hong Kong University and later as a Scientific Expert at Salusmed, based in Hong Kong. She returned to France to join Pfizer, working in medical affairs in the areas of Endocrinology, Transplant and Rheumatology. Audrey later joined Novartis in France, where she progressively advanced to become Business Franchise Head for Ophthalmology and then, in 2020, Country President for the company’s operations in Ireland. Audrey holds a Medical Doctorate from the Paris Faculté de Médécine Cochin, and a Bachelor of Science in Medical Biology.

Audrey Duval Derveloy

Executive vice-president, Global Head of Corporate Affairs, Sanofi

“For the past two years, I have witnessed every day the unwavering commitment of our employees in France to serving patients around the world. Behind each of our successes, from the launch of Beyfortus against RSV, to the environmental transition of our industrial sites, to the mobilization of thousands of employees in support of our partnership with Paris 2024, we had the Corporate Affairs teams at our side. It is with the strength of these successes in mind that I take on these new responsibilities as we continue to modernize Sanofi and pursue our ambition to become an immunology powerhouse.”

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations

Sandrine Guendoul |  25 | 

Nicolas Obrist |  55 |

Victor Rouault |  40 | 

Evan Berland | |

Timothy Gilbert |  9 |

Investor Relations

Thomas Kudsk Larsen | 93 |

Alizé Kaisserian |  11 |

Arnaud Delépine |  93 |

Felix Lauscher | + 1 908 612 7239 |

Keita Browne |  6 |

Nathalie Pham |  17 |

Tarik Elgoutni | 7 |

Thibaud Châtelet | 90 | 

Attachments



EN
21/06/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Press Release: Dupixent approved in the US as the first-ever biologic ...

Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD   Dupixent approved in the US as the first-ever biologic medicine for patients with COPD         Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype Following recent approvals in the EU and China, the US approval is based on two landmark phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life comp...

 PRESS RELEASE

Communiqué de presse : Dupixent est le premier médicament biologique a...

Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO     Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO Dupixent est indiqué à environ 300 000 adultes aux États-Unis présentant une BPCO inadéquatement contrôlée et un phénotype éosinophilique.  L’approbation de ce médicament aux États-Unis fait suite à celle de l’Union européenne et de la Chine et repose sur deux études phares de phase III ayant montré que le Dupixent a permis de réduire significativement les exac...

 PRESS RELEASE

Press Release: Dupixent approved in China as the first-ever biologic m...

Press Release: Dupixent approved in China as the first-ever biologic medicine for patients with COPD Dupixent approved in China as the first-ever biologic medicine for patients with COPD Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved lung function, and also improved health-related quality of lifeCOPD is the most prevalent chronic respiratory disease in China, and is a priority within the government’s Healthy China 2030 public health plan ...

 PRESS RELEASE

Communiqué de presse : Dupixent, premier médicament biologique approuv...

Communiqué de presse : Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO Dupixent, premier médicament biologique approuvé en Chine pour le traitement de la BPCO Cette approbation fait suite à celle obtenue dans l’Union européenne pour le traitement des adultes atteints de bronchopneumopathie chronique obstructive présentant une augmentation des éosinophiles dans le sang, et repose sur deux études phares de phase III ayant montré que le Dupixent réduit significativement les exacerbations et améliore la fonction respiratoire, ainsi que la qualité de vie ...

 PRESS RELEASE

Press Release: Availability of the Q3 2024 Aide mémoire

Press Release: Availability of the Q3 2024 Aide mémoire Availability of the Q3 2024 Aide mémoire Paris, France – September 26, 2024. Sanofi announced today that its Q3 2024 Aide mémoire is available on the "Investors" page of the company's website: As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's third-quarter 2024 results will be published on October 25, 2024. A...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch